Precision Modulation of Gut Microbiome via Metagenomic-driven Dietary and Probiotic Interventions for Non-alcoholic Fatty Liver Disease Management in Obese Saudis
Journal of Advanced Trends in Medical Research · 2025
DOI: 10.4103/atmr.atmr_101_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Advanced Trends in Medical Research, 2025. Verfasst von Mohamadomar Mustafa Alherfi und 8 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Non-alcoholic fatty liver disease (NAFLD) is one of the causes of chronic liver diseases. Inconsistency in the microbiome population of individual guts and host–microbial interactions leads to low response in dietary and pharmacological-based treatments. This study aimed to develop and evaluate a metagenomic-guided, culturally adapted dietary and probiotic intervention to reduce hepatic fat and improve metabolic outcomes in obese Saudi adults with NAFLD. Materials and Methods: We combined gut metagenomic analysis, machine learning-based diet modelling and tailored probiotic supplementation to create an intervention platform. Probiotic specificity depends on functional deficits in bacteria participating in specific metabolic pathways, particularly bile acid metabolism. This technique supplements medication with microbiome-based drug processing.
Results
At week 24, magnetic resonance imaging–proton density fat fraction (MRI-PDFF) decreased by −3.4 ± 2.2% (control), −8.9 ± 3.1% (diet) and −12.3 ± 3.8% (diet + probiotics); liver fat reduction was significant (analysis of variance (ANOVA) P = 0.0004). In the combined intervention, Faecalibacterium prausnitzii increased 2.3-fold (P = 0.003), faecal butyrate rose from 28.7 ± 4.1 to 45.2 ± 5.6 μmol/g (P = 0.002), faecal deoxycholic acid (fDCA) fell 34% (P = 0.010) with a rise in ursodeoxycholic acid (UDCA) (P = 0.015) and high-sensitivity C-reactive protein declined 42% (6.4 ± 1.7 to 3.7 ± 1.3 mg/L) versus 18% in controls (between-group P = 0.0008).
Conclusion
Our precision-guided approach is a novel, scalable solution to managing NAFLD, leveraging the alignment of interactions between hosts, the microbiome and diet within a cultural context. The framework has the potential to optimise therapeutic response in high-risk Saudi communities, and the individual modulation of microbiomes on metabolic diseases is highlighted.
Zitieren
APA
Alherfi, M. M., Khazna, M. S., Aldakhil, A. M., Alghamdi, S. S., Altahhan, M. E., Alalwani, J. F., Asiri, F. S. H., Alkhars, A. H. A., & Mohaini, M. A. (2025). Precision Modulation of Gut Microbiome via Metagenomic-driven Dietary and Probiotic Interventions for Non-alcoholic Fatty Liver Disease Management in Obese Saudis. Journal of Advanced Trends in Medical Research. https://doi.org/10.4103/atmr.atmr_101_25
Vancouver
Alherfi MM, Khazna MS, Aldakhil AM, Alghamdi SS, Altahhan ME, Alalwani JF, et al. Precision Modulation of Gut Microbiome via Metagenomic-driven Dietary and Probiotic Interventions for Non-alcoholic Fatty Liver Disease Management in Obese Saudis. Journal of Advanced Trends in Medical Research. 2025. doi:10.4103/atmr.atmr_101_25
BibTeX
@article{Alherfi2025,
author = {Alherfi, Mohamadomar Mustafa and Khazna, Miyad Subhi and Aldakhil, Abdullah Mohammed and Alghamdi, Sarah Saeed and Altahhan, Mais Ehab and Alalwani, Jana Fahad and Asiri, Faisal Sultan Hadish and Alkhars, Ali Hussein Ali and Mohaini, Mohammad Al},
title = {Precision Modulation of Gut Microbiome via Metagenomic-driven Dietary and Probiotic Interventions for Non-alcoholic Fatty Liver Disease Management in Obese Saudis},
journal = {Journal of Advanced Trends in Medical Research},
year = {2025},
doi = {10.4103/atmr.atmr_101_25}
}
EUVIMED